AVM Biotechnology, LLC

Jan 20, 2021

AVM Biotechnology's Executive Leadership Team Joined by Dr. Manon Cox, MBA, former Protein Sciences Corporation CEO and Dr. Gary Grohmann, former Australian Regulatory Official

Oct 14, 2020

No Aborted Fetal Material in AVM Biotechnology's COVID-19 Treatment Drug

Sep 16, 2020

Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its "supercharged" version of dexamethasone

Jul 08, 2020

AVM Biotechnology Expands Executive Team in Preparation for Oncology & COVID-19 Clinical Trials, Appoints Janet R. Rea, MSPH, Chief Operating Officer

Jun 11, 2020

AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute

Jun 10, 2020

International Vaccine Experts Join AVM Board, Support COVID-19 Treatment

Apr 14, 2020

AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment